Review
Immunology
Lluis Rusinol, Elena Carmona-Rocha, Lluis Puig
Summary: Significant advances in psoriasis treatment have been achieved with the introduction of biologics, especially the newer ones targeted to IL-23/IL-17 pathways. Real-world data is generally consistent with clinical trial results, confirming the efficacy and safety of these biologics.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Ahmed I. Mourad, Robert Gniadecki
Summary: Drug survival studies in psoriasis assessed the comparative effectiveness of biologics like ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab in real-world settings. Results showed ustekinumab had the longest persistence, with adalimumab outperforming etanercept and infliximab at 5 years. The estimated pooled 2- and 5-year drug survival rates can serve as a useful tool for patient communication and clinical decision-making.
FRONTIERS IN MEDICINE
(2021)
Article
Dermatology
Cristina Galache-Osuna, Sebastian Reyes-Garcia, Esther Salgueiro, Javier Bordallo-Landa, Ana Lozano, Francisco Vazquez-Lopez, Jorge Santos-Juanes
Summary: This study aimed to evaluate the long-term survival of apremilast and its predictive factors when used to treat psoriasis. The results showed that apremilast may be a suitable and efficient alternative for the treatment of psoriasis patients in the PASI<10 group.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Eran Galili, Shir Rubinstein Levy, Ido Tzanani, Oz Segal, Anna Lyakhovitsky, Aviv Barzilai, Sharon Baum
Summary: A significant proportion of patients with guttate psoriasis continue to have active disease after diagnosis. Persistent guttate psoriasis is associated with male sex, multiple flares, switch to the vulgaris phenotype, and palmoplantar involvement.
Article
Dermatology
Julian Distel, Simone Cazzaniga, S. Morteza Seyed Jafari, Vladimir Emelianov, Christoph Schlapbach, Nikhil Yawalkar, Kristine Heidemeyer
Summary: This study analyzed the characteristics, effectiveness, and drug survival of patients with psoriasis treated with apremilast in a real-world setting. The drug survival rate at 6, 12, and 24 months after therapy initiation was 69.5%, 34.7%, and 25.8% respectively. Most therapy discontinuations were due to loss of efficacy and adverse events. At 24 months, 35.9% of patients achieved PASI75 response, and 23.7% achieved PASI90 response.
Article
Dermatology
Clarisse Marcombes, Laetitia Penso, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik, Emilie Sbidian
Summary: This study compared the long-term persistence of different biologics in psoriasis treatment. It found that as a second-line treatment, IL-23 inhibitors had longer persistence compared to TNF inhibitors, IL-17 inhibitors, and IL-12/IL-23 inhibitors. The choice of first-line treatment also affected the persistence of second-line treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Review
Dermatology
A. Al-Hammadi, Z. Ruszczak, G. Magarinos, C-Y Chu, Y. El Dershaby, N. Tarcha
Summary: Continuous treatment with biologic agents is more effective than intermittent treatment for moderate-to-severe psoriasis, but intermittent treatment can be a viable option for patients who are unable or unwilling to maintain continuous therapy. Most patients are able to re-establish disease control following re-treatment, and adverse reactions during re-treatment are similar to those observed during continuous dosing.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Pharmacology & Pharmacy
Neslihan Akdogan, Sibel Dogan, Ecem Bostan, Duygu Gulseren, Basak Yalici-Armagan, Gonca Elcin, Sibel Ersoy Evans, Aysen Karaduman, Nilgun Atakan
Summary: The demand for biologic switching is increasing for various reasons. Factors associated with increased risk of multiple switches include younger age and presence of psoriatic arthritis (PsA). Ustekinumab and secukinumab have superior drug survival rates compared to adalimumab in transitioning from second-line to third-line biologics.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Dermatology
N. Loft, A. Egeberg, M. K. Rasmussen, L. E. Bryld, C. Nissen, T. N. Dam, K. K. Ajgeiy, L. Iversen, L. Skov
Summary: This study aims to identify and characterize patients with treatment refractory psoriasis and patients who are super-responders to biologic treatment. The results showed that treatment refractory patients had higher body weight, while super-responders had fewer comorbidities and higher socioeconomic status.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Dermatology
Florence Assan, Florence Tubach, Hugo Arlegui, Manuelle Viguier, Marie Beylot-Barry, Alain Dupuy, Nathalie Beneton, Pascal Joly, Denis Jullien, Emmanuel Mahe, Carle Paul, Marie-Aleth Richard, Herve Bachelez, Caroline Giboin, Olivier Chosidow, Emilie Sbidian
Summary: This study compared obese and non-obese patients in terms of first-line biologic therapy for psoriasis, finding that obese patients had shorter drug survival mainly due to inefficacy.
Article
Dermatology
M. Gooderham, A. Pinter, L. K. Ferris, R. B. Warren, T. Zhan, J. Zeng, A. M. Soliman, C. Kaufmann, B. Kaplan, H. Photowala, B. Strober
Summary: This study analyzed the efficacy and improvement in quality of life in patients with moderate-to-severe plaque psoriasis treated with Risankizumab. The results showed that a higher proportion of patients in the Risankizumab group achieved absolute PASI thresholds compared to the ustekinumab group, and achieved them in a shorter time. Among patients treated with long-term Risankizumab, over 90% achieved PASI <= 3, and over 80% achieved DLQI 0/1. Patients with low absolute PASI scores also had low mean absolute DLQI scores throughout the 172 weeks of continuous Risankizumab treatment.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
David A. Baran, Justin Lansinger, Ashleigh Long, John M. Herre, Amin Yehya, Edward J. Sawey, Amit P. Badiye, Wayne Old, Jack Copeland, Kelly Stelling, Hannah Copeland
Summary: The study examined the long-term survival of heart transplants in the recent era, finding no significant differences in post-transplant mortality based on toxicological and historical data. Factors positively associated with survival included lower donor age and shorter ischemic time.
CIRCULATION-HEART FAILURE
(2021)
Article
Dermatology
Asude Kara Polat, Ilteris Oguz Topal, Melek Aslan Kayiran, Ayse Esra Koku Aksu, Sema Aytekin, Filiz Topaloglu Demir, Tugba Ozkok Akbulut, Ilknur Kivanc Altunay, Ezgi Ozkur, Ayse Serap Karadag
Summary: This study evaluated drug survival, factors associated with survival, and adverse effects of using Acitretin for psoriasis treatment. The results showed that having psoriatic arthritis, being under 65 years old, and receiving previous systemic treatment were significant risk factors for drug discontinuation. Although mucocutaneous adverse effects of Acitretin were frequent, severe ones were rare.
DERMATOLOGIC THERAPY
(2021)
Article
Polymer Science
Pierre P. D. Kondiah, Thankhoe A. Rants'o, Sipho Mdanda, Lauwrence M. Mohlomi, Yahya E. Choonara
Summary: This study aimed to create a thermo-responsive nano-hydrogel delivery system for the treatment of psoriasis vulgaris. The results showed that the synthesized drug-delivery system was less toxic to keratinocyte cells compared to the current treatment and had potential value for transdermal drug delivery.
Article
Dermatology
Laura Pina Vegas, Laetitia Penso, Pascal Claudepierre, Emilie Sbidian
Summary: This cohort study suggests that IL-17 inhibitors show higher treatment persistence compared to TNF inhibitors for Psoriasis (PsO) and psoriatic arthritis (PsA). IL-17 inhibitors also demonstrate higher persistence in PsA compared to IL-12/23 inhibitors, with no difference noted for PsO. However, the overall persistence rates for all biologics remain relatively low at 3 years.
Article
Hematology
Maria Gluud, Emil M. H. Pallesen, Terkild B. Buus, Lise Mette Rahbek Gjerdrum, Lise M. Lindahl, Maria R. Kamstrup, Michael Bzorek, Maria Danielsen, Rikke Bech, Madalena N. Monteiro, Edda Blumel, Andreas Willerslev-Olsen, Anders Lykkebo-Valloe, Chella Krishna Vadivel, Thorbjorn Krejsgaard, Charlotte Menne Bonefeld, Carsten Geisler, Juergen C. Becker, Sergei B. Koralov, Lars Iversen, Thomas Litman, Anders Woetmann, Niels Odum
Summary: Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms and increase the risk of bacterial infection. The study found that malignant T cells secrete cytokines that downregulate the expression of filaggrin and filaggrin-2, leading to compromised skin barrier. Treatment with JAK inhibitors can reverse this effect and increase filaggrin expression in patients with advanced CTCL.
Article
Dermatology
Cathrine Dawn Buttner Elgaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Summary: This study retrospectively analyzed the drug survival and effectiveness of interleukin-23 inhibitors in the treatment of psoriasis and psoriatic arthritis in a real-world setting. The results showed that these drugs have high and similar drug survival and effectiveness in patients with difficult-to-treat psoriasis and PsA.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Lydia Ouchene, Anastasiya Muntyanu, Deborah Assayag, Evicka Veilleux, Andy Abril, Giovanni Ferrara, Elaine Yacyshyn, Christian A. Pineau, Elizabeth O'Brien, Murray Baron, Mohammed Osman, Robert Gniadecki, Elena Netchiporouk
Summary: This article introduces dermatologists to the noninfectious inflammatory skin diseases associated with pulmonary involvement and emphasizes the importance of screening and monitoring for lung disease in high-risk patients. It also highlights the need for dermatologists to recognize cutaneous manifestations of lung disease and refer patients to pulmonary specialists for appropriate treatment. The article emphasizes the common pulmonary complications and high mortality rates associated with autoimmune connective tissue diseases, sarcoidosis, vasculitis, and autoimmune blistering diseases.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Editorial Material
Dermatology
Melika Motamedi, Giovanni Ferrara, Elaine Yacyshyn, Mohammed Osman, Andy Abril, Samia Rahman, Elena Netchiporouk, Robert Gniadecki
Summary: Numerous inflammatory, neoplastic, and genetic skin disorders are associated with interstitial lung disease (ILD), the fibrosing inflammation of lung parenchyma that has significant morbidity and mortality. Therefore, the dermatologist plays a major role in the early detection and appropriate referral of patients at risk for ILD.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Letter
Dermatology
Mie Siewertsen, Rownaq Al-Sofi, Hajer Dridi, Gayathri D. D. Ajenthen, Claus Zachariae, Lone Skov, Nikolai Loft
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Nita Katarina Frifelt Wienholtz, Jacob P. P. Thyssen, Casper Emil Christensen, Simon Francis Thomsen, Katrine Elisabeth Karmisholt, Gregor B. E. Jemec, Hans B. B. Lomholt, Michael Heidenheim, Anne Birgitte Simonsen, Carsten Sand, Christian Vestergaard, Diljit Kaur-Knudsen, Elisabeth Ammitzboll, Erik Lorup, Anne G. G. Danielsen, Gitte Strauss, Lone Skov, Peter H. H. Andersen, Marianne Hald, Luise W. W. Idorn, Messoud Ashina, Claus Zachariae, Alexander Egeberg
Summary: This study validates the Rosacea Area and Severity Index (RASI) as an effective tool for evaluating the severity of rosacea, with comparable agreement to the currently used Investigator's Global Assessment (IGA) method. RASI provides a more nuanced evaluation of various rosacea features and the extent of involvement in different facial areas, suggesting its widespread use in clinical and research settings.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Amanda Kvist-Hansen, Hannah Kaiser, Martin Krakauer, Peter M. M. Gortz, Xing Wang, Christine Becker, Claus Zachariae, Peter R. R. Hansen, Lone Skov
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Kulli Kingo, Raquel Rivera Diaz, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh, Piotr Jagiello
Summary: The purpose of this study was to compare the effectiveness of early intervention with secukinumab and traditional nb-UVB phototherapy in patients with new-onset moderate to severe plaque psoriasis. The results showed that secukinumab was more effective than nb-UVB, and early use of biologic treatment may be more effective in treating psoriasis.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Clara Sophie Bramsen Andersen, Amanda Kvist-Hansen, Mie Siewertsen, Christian Enevold, Peter Riis Hansen, Diljit Kaur-Knudsen, Claus Zachariae, Claus Henrik Nielsen, Nikolai Loft, Lone Skov
Summary: This study examined the usefulness of various inflammation biomarkers in personalizing biologic treatment for psoriasis patients. It was found that the neutrophil-to-lymphocyte ratio (NLR) and interleukin-6 (IL-6) levels could serve as predictive biomarkers for treatment response to TNF-alpha inhibitor therapy. The study also measured other biomarkers such as TNF-alpha, IL-1 beta, IFN-alpha, IL-17A, IL-6, soluble IL-6 receptor (sIL-6R), and soluble IL-6 signal transducer (sIL-6ST) in different patient groups.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Aaron M. M. Drucker, Omer Kleiner, Rachael Manion, Anie Philip, Jan Dutz, Kathleen Barnard, Julie Fradette, Lucie Germain, Robert Gniadecki, Ivan Litvinov, Sarvesh Logsetty, Morris Manolson, P. Regine Mydlarski, Vincent Piguet, Debbie Ward, Youwen Zhou, An-Wen Chan
Summary: The Skin Investigation Network of Canada (SkIN Canada) identified the top ten research priorities for nine key skin conditions through surveys, scoping reviews, and workshops, emphasizing the importance of involving patients and healthcare providers.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2023)
Letter
Dermatology
Morten Bahrt Haulrig, Nikolai Loft, Christopher Willy Schwarz, Frederik Boetius Hertz, Simon Francis Thomsen, Susanne Dam Nielsen, Lone Skov
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
David Thein, Nana A. L. Roseno, Julia-Tatjana Maul, Jashin J. Wu, Lone Skov, Lars Erik Bryld, Mads K. Rasmussen, Kawa Khaled Ajgeiy, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg
Summary: The real-world effectiveness of biologics in treating psoriasis was examined using a nationwide registry. The results showed that the risk of discontinuation or off-label dose escalation was lower for secukinumab compared to ustekinumab, but higher for adalimumab. However, the risk of discontinuation was higher for both secukinumab and adalimumab. For patients who were bio-naive, the risk of discontinuation was comparable between secukinumab and ustekinumab.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Cathrine Dawn Buttner Elgaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Summary: This study investigates the drug survival and clinical effectiveness of brodalumab in real-world patients with psoriasis and psoriatic arthritis. The results show that brodalumab is effective in treating these conditions, but the drug survival rate is lower compared to other studies.
Article
Immunology
Hakim Ben Abdallah, Sabine Seeler, Anne Bregnhoj, Gautam Ghatnekar, Lasse S. Kristensen, Lars Iversen, Claus Johansen
Summary: RGRN-305, an HSP90 inhibitor, exhibits anti-inflammatory effects by suppressing key proinflammatory cytokines and signaling pathways in TPA-induced skin inflammation. This study suggests that HSP90 inhibition may be a novel mechanism of action for treating immune-mediated skin diseases beyond psoriasis, and it may serve as a topical treatment option.
FRONTIERS IN IMMUNOLOGY
(2023)